Boehringer Ingelheim receives FDA approval for COMBIVENT RESPIMAT to treat COPD

[News]

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved COMBIVENT RESPIMAT, a new, propellant-free inhaler product that uses a slow-moving mist to deliver the same active ingredients of COMBIVENT Inhalation Aerosol in a metered dose inhaler.

More... (http://www.news-medical.net/news/20111010/Boehringer-Ingelheim-receives-FDA-approval-for-COMBIVENT-RESPIMAT-to-treat-COPD.aspx)